Related Experiment Videos
Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
J Alvarez-Nemegyei1, A Cobarrubias-Cobos, F Escalante-Triay
1Rheumatology Department, Centro Médico Nacional El Fenix, Mérida, Yucatán, Mexico.
Lupus
|September 15, 1998
Summary
Bromocriptine (BRC) effectively reduced systemic lupus erythematosus (SLE) flares in patients. This study found BRC safe and beneficial for managing SLE disease activity and reducing flare frequency.
Area of Science:
- Rheumatology
- Endocrinology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant morbidity.
- Elevated prolactin (PRL) levels have been observed in some SLE patients.
- Conventional treatments for SLE can have side effects and may not fully control disease activity.
Purpose of the Study:
- To evaluate the efficacy and safety of bromocriptine (BRC) as an add-on therapy for SLE.
- To assess the impact of BRC on disease activity, flare rates, and prolactin levels in SLE patients.
Main Methods:
- A prospective, double-blind, randomized, placebo-controlled trial.
- 66 SLE patients were randomized to receive either 2.5 mg daily bromocriptine or placebo.
- Disease activity was measured by SLE Disease Activity Index (SLEDAI), and flare rates were recorded over a mean follow-up of 12.5 months.
Main Results:
- Bromocriptine significantly reduced serum prolactin levels compared to placebo.
- SLEDAI scores were significantly lower in the BRC group.
- The mean number of SLE flares per patient per month was significantly reduced with bromocriptine treatment.
Conclusions:
- Low-dose bromocriptine is a safe and effective adjunctive treatment for reducing SLE flares.
- BRC may help manage disease activity in SLE patients, potentially through prolactin modulation.